NervGen Pharma Corp. (NGENF)
USD 2.02
(0.97%)
USD 2.02
(0.97%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 17.77 Million CAD | -22.79% |
| 2022 | 23.02 Million CAD | 79.73% |
| 2021 | 12.81 Million CAD | 14.43% |
| 2020 | 11.19 Million CAD | 13.5% |
| 2019 | 9.86 Million CAD | 626.14% |
| 2018 | 1.35 Million CAD | 11399.9% |
| 2017 | 11.81 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5 Million CAD | 3.39% |
| 2024 Q2 | 5.98 Million CAD | 19.71% |
| 2023 Q2 | 4.76 Million CAD | 1.12% |
| 2023 Q1 | 4.71 Million CAD | -30.47% |
| 2023 FY | 17.63 Million CAD | -23.42% |
| 2023 Q3 | 3.41 Million CAD | -28.38% |
| 2023 Q4 | 4.83 Million CAD | 41.58% |
| 2022 FY | 23.02 Million CAD | 79.73% |
| 2022 Q4 | 6.78 Million CAD | 37.78% |
| 2022 Q3 | 4.92 Million CAD | -22.01% |
| 2022 Q2 | 6.31 Million CAD | 26.15% |
| 2022 Q1 | 5 Million CAD | 20.69% |
| 2021 Q2 | 2.76 Million CAD | 24.09% |
| 2021 Q1 | 2.23 Million CAD | -49.47% |
| 2021 Q3 | 3.66 Million CAD | 32.51% |
| 2021 Q4 | 4.14 Million CAD | 13.08% |
| 2021 FY | 12.81 Million CAD | 14.43% |
| 2020 FY | 11.19 Million CAD | 13.5% |
| 2020 Q1 | 2.27 Million CAD | -21.77% |
| 2020 Q4 | 4.41 Million CAD | 115.17% |
| 2020 Q3 | 2.05 Million CAD | -16.54% |
| 2020 Q2 | 2.45 Million CAD | 8.12% |
| 2019 Q3 | 2.36 Million CAD | 50.72% |
| 2019 Q4 | 2.9 Million CAD | 22.84% |
| 2019 FY | 9.86 Million CAD | 626.14% |
| 2019 Q2 | 1.56 Million CAD | -48.09% |
| 2019 Q1 | 3.02 Million CAD | 293.71% |
| 2018 Q1 | 10.62 Thousand CAD | 42.51% |
| 2018 Q2 | 64.35 Thousand CAD | 505.7% |
| 2018 FY | 1.35 Million CAD | 11399.9% |
| 2018 Q3 | 515.54 Thousand CAD | 701.15% |
| 2018 Q4 | 767.96 Thousand CAD | 48.96% |
| 2017 FY | 11.81 Thousand CAD | 0.0% |
| 2017 Q3 | 3367.00 CAD | 643.27% |
| 2017 Q4 | 7455.00 CAD | 121.41% |
| 2017 Q2 | 453.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Qrons Inc. | 643.67 Thousand USD | -2661.744% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 69.052% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -63.584% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 52.285% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -4178.606% |
| BioStem Technologies, Inc. | 22.97 Million USD | 22.625% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 39.848% |
| Skye Bioscience, Inc. | 13.54 Million USD | -31.217% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2577.215% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -252.57% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1231.159% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -4463.209% |
| Nascent Biotech, Inc. | 2.22 Million USD | -697.205% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -11.033% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 79.516% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -261.469% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -6692.107% |
| SQZ Biotechnologies Company | 85.61 Million USD | 79.237% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -509.577% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1083.616% |
| Mesoblast Limited | 5.9 Million USD | -201.198% |
| Marizyme, Inc. | 19.23 Million USD | 7.605% |
| Genus plc | 147.7 Million USD | 87.964% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -102.486% |
| Pharming Group N.V. | 225.49 Million USD | 92.116% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -767.705% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1225.092% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -113.176% |
| ContraFect Corporation | 56.88 Million USD | 68.752% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -303.221% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1102.143% |
| IMV Inc. | 37.7 Million USD | 52.858% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -537.077% |
| MultiCell Technologies, Inc. | 567.42 USD | -3132801.554% |
| ONE Bio Corp. | 6.44 Million USD | -175.869% |
| Accustem Sciences Inc. | 3.74 Million USD | -374.499% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 79.316% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -3241.726% |
| Q BioMed Inc. | 3.43 Million USD | -417.272% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 28.073% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -576.558% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1688.074% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 82.103% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -910.225% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -164.613% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -853.497% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 71206.84% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -868.708% |
| GB Sciences, Inc. | 1.42 Million USD | -1151.432% |
| Alpha Cognition Inc. | 9.7 Million USD | -83.159% |
| HST Global, Inc. | 140.9 Thousand USD | -12515.917% |
| CSL Limited | 3.44 Billion USD | 99.485% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1480.278% |
| Halberd Corporation | 74.84 Thousand USD | -23652.318% |
| Enzolytics Inc. | 2.17 Million USD | -715.63% |
| Agentix Corp. | 1.37 Million USD | -1195.909% |
| Resverlogix Corp. | 12.71 Million USD | -39.842% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -386.939% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.841% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1602.75% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -639.177% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1025.568% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -422.08% |
| AVAX Technologies, Inc. | 7.31 Million USD | -143.175% |
| Zenith Capital Corp. | 8.94 Million USD | -98.778% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.846% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -101941.846% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -624.009% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -10264.885% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -825.434% |
| Kadimastem Ltd | 2.41 Million USD | -637.589% |
| Helix BioMedix, Inc. | 1.97 Million USD | -801.44% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -9695.14% |
| LadRx Corporation | 3.81 Million USD | -366.361% |
| Cell Source, Inc. | 4.32 Million USD | -310.989% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1824.907% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1824.907% |
| NovAccess Global Inc. | 2.46 Million USD | -620.65% |
| Affymax, Inc. | 39.38 Million USD | 54.865% |
| Itoco Inc. | 919.14 Thousand USD | -1834.053% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -319.419% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1488.625% |
| Mobile Lads Corp. | 554.54 Thousand USD | -3105.633% |
| CytoDyn Inc. | 18.05 Million USD | 1.558% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -70529.385% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -7977.459% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1152.064% |
| SYBLEU INC | 160.87 Thousand USD | -10949.945% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -878.721% |
| International Stem Cell Corporation | 5.27 Million USD | -237.255% |
| Bioxytran, Inc. | 3.82 Million USD | -365.341% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -33669.063% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -87284.899% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 50.982% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -998.684% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2315.855% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -471.415% |
| Neutra Corp. | 243.82 Thousand USD | -7190.886% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1.831% |
| PureTech Health plc | 144.59 Million USD | 87.706% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 13.242% |
| IXICO plc | 4.7 Million USD | -277.665% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -102.077% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 84.903% |
| CSL Limited | 3.89 Billion USD | 99.543% |
| Cellectis S.A. | 97.32 Million USD | 81.734% |